Redeye expected higher sales and lower Opex compared to Powercell’s reported Q1 numbers.
Redeye thinks investors’ patience has run out after Enea posted its third consecutive quarter with n...
Verkkokauppa.com’s Q1 topline topped, but EBIT fell short of our expectations as well as consensus e...
Solteq’s Q1 was in line with our expectations, with revenue at EUR 19.
DT’s supply chain issues continued, and the company’s Q1 result fell short of our expectations.
Redeye provides a preview ahead of Embracers Q4 21/22 report due on 19th of May.
Redeye returns with a follow-up note to Genovis’ Q1’22 report.
Redeye comments on Spago’s Q1 2022 report and the company update presented yesterday.
Redeye is encouraged by yesterday’s news that Lipigon’s phase I trial with Lipisense has been approv...
Sales SEK 613m +2.9% vs ABGSC 596m EBIT -33% y-o-y, -26% vs.
Redeye sees a solid Q1 report from Fortnox with a stronger than expected ARPC, likely driven by incr...
Redeye comments on Carasent’s Q1 report, which was solid albeit somewhat below our sales estimates.
Redeye states that both net sales and EBIT missed expectations slightly.
Redeye comments on Invisio ahead of its Q1-results (due May 4) where we expect continued muted growt...
Redeye updates estimates and valuation on EG7 ahead of its Q1-results (due May 25) where we expected...
Sales -3% vs. ABGSCe Adj. EBITDA 14% vs. ABGSCe We expect cons.
Redeye comments on Urb-it’s Q1 report, which showed revenue growth of 124% Y/Y but well below our ex...
Redeye sees a solid Q1 report from Vertiseit, with stronger sales and EBIT than we expected.
Redeye comments on Evolution’s Q1-results that came in slightly above our expectations.
Sales -11% vs ABGSCe (SEK 10.9m vs ABGSCe 12.3m) As we expected, Q1 came in seasonally softer… … but...
